Licensing agreement gives Elevation Oncology access to Synaffix's ADC technology for one program in combination with SYNstatin E™ Elevation Oncology nominates a novel HER3 ADC candidate EO-1022 ...
Synaffix’s glycan-based antibody–drug conjugate technology is experiencing strong demand, based on its potential to improve safety and efficacy of cancer therapies without genetic engineering.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results